Voyager Therapeutics (MEX:VYGR) Current Deferred Revenue: MXN4.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VYGR Voyager Therapeutics Inc MEX:VYGR
52 GF Score
Price MXN63.00
GF Value MXN28.67
! 6 Warning Signs
View Full Analysis

What is Voyager Therapeutics Current Deferred Revenue?

Voyager Therapeutics MEX:VYGR 52 Current Deferred Revenue is MXN4.3 Mil as of Jun. 2026. GuruFocus rates MEX:VYGR with a GF Score™ of 52/100 and a GF Value™ of MXN28.67. The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Voyager Therapeutics's current deferred revenue for the quarter that ended in Jun. 2026 was MXN4.3 Mil.

Voyager Therapeutics Current Deferred Revenue Related Terms

Voyager Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Current Deferred Revenue Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 695.14 1,157.61 727.87 508.75 28.63

Voyager Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 386.32 194.05 28.63 7.12 4.26
MEX:VYGR
52GF Score
Voyager Therapeutics Inc MEX:VYGR
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of MXN4.3 Mil mean?
Voyager Therapeutics (MEX:VYGR) has a Current Deferred Revenue of MXN4.3 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Current Deferred Revenue too high?
Voyager Therapeutics' current Current Deferred Revenue is MXN4.3 Mil. Overall, Voyager Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Current Deferred Revenue compare to CHRS and KROS?
Voyager Therapeutics' Current Deferred Revenue of MXN4.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Current Deferred Revenue is MXN4.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Voyager Therapeutics (MEX:VYGR) has a current Current Deferred Revenue of MXN4.3 Mil. The stock's GF Value™ is MXN28.67, compared to a current price of MXN63.00 — trading 119.7% above its estimated fair value. The current Current Deferred Revenue is MXN4.3 Mil. Voyager Therapeutics' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Voyager Therapeutics (MEX:VYGR), the current Current Deferred Revenue is MXN4.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (MEX:VYGR) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of MXN63.00 is trading 119.7% above its estimated GF Value™ of MXN28.67.

Key valuation signals for MEX:VYGR:

  • Current Deferred Revenue: MXN4.3 Mil
  • GF Value™: MXN28.67 vs. price of MXN63.00 (119.7% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the MEX:VYGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVT6:Germany
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score

Get the complete analysis for MEX:VYGR

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN63.00
Price
MXN28.67
GF Value